 |
인쇄하기
취소
|
LG conducts Phase II trials for new antidiabetic agent
LG Life Sciences says it has conducted Phase II trials of its new dipeptidyl peptidase IV (LC15-0444) for the treatment of type II diabetes.
Results of Phase I trial in 90 diabetic patients, conducted in Seoul National University Hospital, demonstrated the efficacy and safety of LC15-0444, according to the company.
DPP-IV inactivates glucagon-like peptide-1 (GLP-1), an important mediator ...
Results of Phase I trial in 90 diabetic patients, conducted in Seoul National University Hospital, demonstrated the efficacy and safety of LC15-0444, according to the company.
DPP-IV inactivates glucagon-like peptide-1 (GLP-1), an important mediator ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.